CY1107851T1 - Παραγωγα πυρολλο-πυριδινης και η χρηση τους ως ανταγωνιστων crth2 - Google Patents

Παραγωγα πυρολλο-πυριδινης και η χρηση τους ως ανταγωνιστων crth2

Info

Publication number
CY1107851T1
CY1107851T1 CY20081100039T CY081100039T CY1107851T1 CY 1107851 T1 CY1107851 T1 CY 1107851T1 CY 20081100039 T CY20081100039 T CY 20081100039T CY 081100039 T CY081100039 T CY 081100039T CY 1107851 T1 CY1107851 T1 CY 1107851T1
Authority
CY
Cyprus
Prior art keywords
pyrollo
crth2
competitors
pyridine products
pyridine
Prior art date
Application number
CY20081100039T
Other languages
English (en)
Inventor
Kamlesh Bala
Catherine Leblanc
David Andrew Sandham
Katharine L Turner
Simon James Watson
Lyndon Nigel Brown
Brian Cox
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0413619A external-priority patent/GB0413619D0/en
Priority claimed from GB0507693A external-priority patent/GB0507693D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1107851T1 publication Critical patent/CY1107851T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Application Of Or Painting With Fluid Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Παρέχονται, σύμφωνα με την εφεύρεση, ενώσεις του χημικού τύπου (I) σε ελεύθερη μορφή ή υπό την μορφή άλατος, όπου τα R1, R2, R3, R4, R5, R6, Q, W, Χ, m, n και p είναι όπως ορίστηκαν στην περιγραφή, διαδικασία για την παρασκευή τους και η χρήση τους ως φαρμακευτικά σκευάσματα.
CY20081100039T 2004-06-17 2008-01-10 Παραγωγα πυρολλο-πυριδινης και η χρηση τους ως ανταγωνιστων crth2 CY1107851T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0413619A GB0413619D0 (en) 2004-06-17 2004-06-17 Organic compounds
GB0507693A GB0507693D0 (en) 2005-04-15 2005-04-15 Organic compounds
EP05751627A EP1761529B3 (en) 2004-06-17 2005-06-16 Pyrrolopyridine derivatives and their use as crth2 antagonists

Publications (1)

Publication Number Publication Date
CY1107851T1 true CY1107851T1 (el) 2013-06-19

Family

ID=35510318

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100039T CY1107851T1 (el) 2004-06-17 2008-01-10 Παραγωγα πυρολλο-πυριδινης και η χρηση τους ως ανταγωνιστων crth2

Country Status (29)

Country Link
US (5) US7666878B2 (el)
EP (1) EP1761529B3 (el)
JP (1) JP4886680B2 (el)
KR (1) KR101183330B1 (el)
AR (1) AR049443A1 (el)
AT (1) ATE378338T1 (el)
AU (1) AU2005254681B2 (el)
BR (1) BRPI0512060B8 (el)
CA (1) CA2569125C (el)
CY (1) CY1107851T1 (el)
DE (1) DE602005003365T3 (el)
DK (1) DK1761529T3 (el)
EC (1) ECSP067077A (el)
ES (1) ES2294717T7 (el)
HK (1) HK1103730A1 (el)
HR (1) HRP20080022T4 (el)
IL (1) IL179604A (el)
MA (1) MA28666B1 (el)
MX (1) MXPA06014694A (el)
MY (1) MY144903A (el)
NO (1) NO338319B1 (el)
NZ (1) NZ551439A (el)
PE (1) PE20060301A1 (el)
PL (1) PL1761529T6 (el)
PT (1) PT1761529E (el)
RS (1) RS50552B (el)
RU (1) RU2379309C2 (el)
TW (1) TWI352702B (el)
WO (1) WO2005123731A2 (el)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY144903A (en) 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
GB0525143D0 (en) * 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525144D0 (en) * 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525337D0 (en) * 2005-12-13 2006-01-18 Novartis Ag Organic compounds
EP1986633B1 (en) 2006-02-10 2014-07-30 Summit Corporation Plc Treatment of duchenne muscular dystrophy
GB0611695D0 (en) * 2006-06-13 2006-07-26 Novartis Ag Organic compounds
AU2007282949B8 (en) 2006-08-07 2012-10-04 Actelion Pharmaceuticals Ltd. (3-Amino-1,2,3,4-tetrahydro-9H-carbazol-9-yl)-acetic acid derivatives
AR068332A1 (es) * 2007-08-03 2009-11-11 Summit Corp Plc Combinaciones de drogas para el tratamiento de la distrofia muscular de duchenne
GB0715937D0 (en) * 2007-08-15 2007-09-26 Vastox Plc Method of treatment og duchenne muscular dystrophy
EP2268281A4 (en) 2008-02-15 2012-05-02 Abbott Lab THIENOPYRROLES AND PYRROLOTHIAZOLES AS NEW THERAPEUTIC AGENTS
SI2318006T1 (sl) * 2008-08-15 2017-01-31 Nivalis Therapeutics, Inc. Novi pirolni inhibitorji S-nitrozoglutation reduktaze kot terapevtska sredstva
US8642628B2 (en) 2008-08-15 2014-02-04 N30 Pharmaceuticals, Inc. Pyrrole inhibitors of S-nitrosoglutathione reductase
JP5688366B2 (ja) 2008-08-15 2015-03-25 エヌサーティー・ファーマシューティカルズ・インコーポレーテッド 治療薬剤としての、ｓ−ニトロソグルタチオンレダクターゼの新規ピロール阻害剤
TWI562987B (en) 2010-03-22 2016-12-21 Actelion Pharmaceuticals Ltd 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
US9290453B2 (en) 2010-12-23 2016-03-22 Merck Sharp & Dohme Corp. Quinolines and aza-quinolines as CRTH2 receptor modulators
ES2635030T3 (es) * 2010-12-23 2017-10-02 Merck Sharp & Dohme Corp. Quinoxalinas y aza-quinoxalinas como moduladores del receptor CRTH2
EP2697223B1 (en) 2011-04-14 2016-07-13 Actelion Pharmaceuticals Ltd. 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
WO2013061977A1 (ja) 2011-10-25 2013-05-02 塩野義製薬株式会社 Ｐｇｄ２受容体アンタゴニスト活性を有するへテロ環誘導体
US20140328861A1 (en) 2011-12-16 2014-11-06 Atopix Therapeutics Limited Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis
PL3119779T3 (pl) 2014-03-17 2019-01-31 Idorsia Pharmaceuticals Ltd Pochodne kwasu azaindolooctowego i ich zastosowanie jako modulatorów receptora prostaglandyny d2
JP6484644B2 (ja) 2014-03-18 2019-03-13 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ アザインドール酢酸誘導体及びプロスタグランジンｄ２受容体調節剤としてのそれらの使用
SG11201700777VA (en) 2014-08-04 2017-02-27 Nuevolution As Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
WO2017015418A1 (en) 2015-07-23 2017-01-26 Merck Sharp & Dohme Corp. Genetic markers associated with response to crth2 receptor antagonists
MX2018003202A (es) 2015-09-15 2018-06-08 Idorsia Pharmaceuticals Ltd Formas cristalinas.
AU2016328150B2 (en) 2015-09-23 2020-10-01 Xw Laboratories Inc. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
SI3356329T1 (sl) * 2015-09-29 2020-08-31 Novartis Ag Postopek priprave 1-(4-metansulfonil-2-trifluorometil-benzil)-2-metil- 1H-pirolo (2,3-b)piridin-3-il-ocetne kisline
WO2017210261A1 (en) * 2016-05-31 2017-12-07 Concert Pharmaceuticals, Inc. Deuterated fevipiprant
ES2921432T3 (es) 2016-06-13 2022-08-25 Gilead Sciences Inc Derivados de azetidina como moduladores de FXR (NR1H4)
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
CN106188040B (zh) * 2016-06-28 2018-03-23 浙江宏鑫染化材料有限公司 一种Fevipiprant及其中间体的制备方法
WO2018014867A1 (zh) 2016-07-21 2018-01-25 正大天晴药业集团股份有限公司 作为crth2抑制剂的三并环类化合物
ES2927019T3 (es) 2017-03-28 2022-11-02 Gilead Sciences Inc Combinaciones terapéuticas para el tratamiento de enfermedades hepáticas
EP3601235A4 (en) 2017-03-30 2020-11-18 XW Laboratories Inc. BICYCLIC HETERARYL DERIVATIVES, PREPARATION AND ASSOCIATED USES
JOP20190223A1 (ar) 2017-04-01 2019-09-26 Novartis Ag عملية لتحضير حمض 1-(4- ميثان سلفونيل -2- تراي فلورو ميثيل - بنزيل)-2- ميثيل -1h- بيرولو [2، 3-b] بيريدين -3- يل- أسيتيك
JP7221227B2 (ja) 2017-06-30 2023-02-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 発毛を調節するための組成物及び方法
WO2019011337A1 (zh) * 2017-07-14 2019-01-17 苏州科睿思制药有限公司 Qaw-039的晶型及其制备方法和用途
WO2019130166A1 (en) * 2017-12-26 2019-07-04 Mankind Pharma Ltd. Preparation of 2-[2-methyl-1-[[4-methylsulfonyl-2-(trifluoro methyl)phenyl]methyl] pyrrolo[2,3-b]pyridin-3-yl]acetic acid
AU2019209725B2 (en) 2018-01-19 2023-03-09 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Crystal form of indole derivative and preparation method and use thereof
CN110467612B (zh) * 2018-05-09 2020-09-25 新发药业有限公司 一种前列腺素d2受体抑制剂化合物的简便制备方法
EP3856719B1 (en) 2018-09-30 2023-06-07 XWPharma Ltd. Compounds as neuronal histamine receptor-3 antagonists and uses thereof
DK3911647T3 (da) 2019-01-15 2024-02-26 Gilead Sciences Inc Isoxazol-forbindelse som FXR-agonist og farmaceutiske sammensætninger, der omfatter en sådan
CN113439078B (zh) 2019-02-19 2024-04-23 吉利德科学公司 Fxr激动剂的固体形式
CN115244028A (zh) 2019-12-20 2022-10-25 凯瑞康宁生物工程有限公司 4-缬氨酰氧基丁酸的合成方法
MX2022007265A (es) 2019-12-20 2022-09-09 Nuevolution As Compuestos activos frente a receptores nucleares.
US11780843B2 (en) 2020-03-31 2023-10-10 Nuevolution A/S Compounds active towards nuclear receptors
EP4126875A1 (en) 2020-03-31 2023-02-08 Nuevolution A/S Compounds active towards nuclear receptors
CN115803017A (zh) 2020-06-18 2023-03-14 凯瑞康宁生物工程有限公司 水溶性活性药物成分的药物造粒物
KR20230011359A (ko) 2020-06-18 2023-01-20 엑스더블유파마 리미티드 수용성 활성 약제 성분의 제어 방출 과립화물
CN116261451A (zh) 2020-07-24 2023-06-13 凯瑞康宁生物工程有限公司 γ-羟基丁酸衍生物的药物组合物和药物动力学
JP2023544420A (ja) 2020-10-05 2023-10-23 エックスダブリューファーマ リミテッド ガンマ－ヒドロキシ酪酸誘導体の調節放出組成物
JP2024511991A (ja) 2021-03-19 2024-03-18 エックスダブリューファーマ リミテッド ガンマ－ヒドロキシ酪酸誘導体の組み合わされた放出製剤の薬物動態

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320268A (en) * 1964-08-14 1967-05-16 Merck & Co Inc 1-aroyl or heteroaroyl-7-azaindole-3-carboxylates and derivatives
US5212195A (en) * 1992-05-13 1993-05-18 Syntex (U.S.A.) Inc. Substituted indole antagonists derivatives which are angiotensin II
GB9319297D0 (en) 1993-09-17 1993-11-03 Wellcome Found Indole derivatives
WO1995033748A1 (en) 1994-06-09 1995-12-14 Smithkline Beecham Corporation Endothelin receptor antagonists
JP2891544B2 (ja) * 1994-06-16 1999-05-17 ファイザー・インコーポレーテッド ピラゾロおよびピロロピリジン類
TWI262920B (en) 2000-10-27 2006-10-01 Elbion Ag New 7-azaindoles, their use as inhibitors of phosphodiesterase 4, and a method for synthesizing them
JP4292402B2 (ja) 2001-09-07 2009-07-08 小野薬品工業株式会社 インドール誘導体化合物、それらの製造方法およびそれらを有効成分として含有する薬剤
SE0200411D0 (sv) * 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200356D0 (sv) * 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
AU2003231509A1 (en) * 2002-05-16 2003-12-02 Shionogi And Co., Ltd. Compound exhibiting pgd 2 receptor antagonism
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) * 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
WO2005040112A1 (en) * 2003-10-14 2005-05-06 Oxagen Limited Compounds with pgd2 antagonist activity
GB0412914D0 (en) 2004-06-10 2004-07-14 Oxagen Ltd Compounds
MY144903A (en) * 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
GB0525143D0 (en) * 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525144D0 (en) * 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525337D0 (en) * 2005-12-13 2006-01-18 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
US7666878B2 (en) 2010-02-23
AR049443A1 (es) 2006-08-02
EP1761529B1 (en) 2007-11-14
US20080114022A1 (en) 2008-05-15
US20140309254A1 (en) 2014-10-16
US20100210610A1 (en) 2010-08-19
TW200617009A (en) 2006-06-01
WO2005123731A3 (en) 2006-05-04
US20100204225A1 (en) 2010-08-12
ECSP067077A (es) 2007-01-26
CA2569125A1 (en) 2005-12-29
US9169251B2 (en) 2015-10-27
DK1761529T3 (da) 2008-03-25
BRPI0512060B1 (pt) 2018-08-07
ES2294717T7 (es) 2012-06-14
TWI352702B (en) 2011-11-21
PL1761529T3 (pl) 2008-04-30
RU2007101277A (ru) 2008-07-27
BRPI0512060A (pt) 2008-02-06
EP1761529A2 (en) 2007-03-14
DE602005003365D1 (de) 2011-01-05
AU2005254681B2 (en) 2009-01-29
EP1761529B3 (en) 2011-06-15
HRP20080022T4 (hr) 2011-10-31
CA2569125C (en) 2013-01-08
NZ551439A (en) 2009-09-25
US8455645B2 (en) 2013-06-04
JP2008502638A (ja) 2008-01-31
DE602005003365T2 (de) 2008-09-11
ATE378338T1 (de) 2007-11-15
BRPI0512060B8 (pt) 2021-05-25
MY144903A (en) 2011-11-30
PL1761529T6 (pl) 2011-11-30
RS50552B (sr) 2010-05-07
MA28666B1 (fr) 2007-06-01
PE20060301A1 (es) 2006-05-18
KR101183330B1 (ko) 2012-09-17
US8470848B2 (en) 2013-06-25
NO338319B1 (no) 2016-08-08
ES2294717T3 (es) 2008-04-01
PT1761529E (pt) 2008-02-11
AU2005254681A1 (en) 2005-12-29
IL179604A (en) 2014-04-30
HK1103730A1 (en) 2007-12-28
IL179604A0 (en) 2007-05-15
US20130267518A1 (en) 2013-10-10
KR20070032694A (ko) 2007-03-22
WO2005123731A2 (en) 2005-12-29
MXPA06014694A (es) 2007-02-12
HRP20080022T3 (en) 2008-02-29
NO20070323L (no) 2007-03-12
JP4886680B2 (ja) 2012-02-29
RU2379309C2 (ru) 2010-01-20
DE602005003365T3 (de) 2012-08-30
US8791256B2 (en) 2014-07-29

Similar Documents

Publication Publication Date Title
CY1107851T1 (el) Παραγωγα πυρολλο-πυριδινης και η χρηση τους ως ανταγωνιστων crth2
CY1110247T1 (el) Παραγωγα βενζοκιναζολινης και η χρηση τους στην θεραπεια των διαταραχων των οστων
CY1107915T1 (el) Τρικυκλικες σπιροπιπεριδινες ή σπιροπυρρολιδινες
CY1108894T1 (el) Νεα παραγωγα βενζιμιδαζολης
CY1111822T1 (el) Παραγωγα σπειροϊνδολινοπιπεριδινης ονες
CY1108129T1 (el) Παραγωγα 4-αμινο-6-φαινυλ-πυρρολο[2,3-δ]πυριμιδινης
CY1113858T1 (el) Παραγωγα πυριδιν-3-υλιου ως ανοσορυθμιστικοι παραγοντες
CY1118346T1 (el) Αρυλoαζoλ-2-υλ κυανοαιθυλαμινο ενωσεις, μεθοδος κατασκευης και μεθοδος χρησης αυτων
CY1108094T1 (el) Κινολινικα παραγωγα ως αναστολεις φωσφοδιεστερασης
CY1110332T1 (el) Παραγωγα βενζιμιδαζολης, συνθεσεις που τα περιεχουν, παρασκευη αυτων και χρηση τους
CY1113282T1 (el) Αντιικα νουκλεοζιτικα αναλογα
SE0302811D0 (sv) Novel compounds
CY1113323T1 (el) Ενωσεις τετραϋδροφουρο[3,4-d]διοξολανιου για χρηση στη θεραπεια ιικων μολυνσεων και καρκινου
CY1108254T1 (el) Ενωσεις που επηρεαζουν τη γλυκοκιναση
CY1112311T1 (el) Ενωσεις πυραζολινης ως ανταγωνιστες υποδοχεα αλατοκορτικοειδους
CY1114759T1 (el) Παραγωγα πυριδιν-4-υλι0υ ως s1p1/edg1 αγωνιστες
CY1108754T1 (el) Νεα παραγωγα θειοφαινογλυκοσιδης, μεθοδος για την παρασκευη τους, φαρμακα περιεχοντα αυτες τις ενωσεις και η χρηση τους
CY1108306T1 (el) Αναστολεις αζαϊνδολιου των mtp και apob
CY1110835T1 (el) Διφαινυλ παραγωγα και η χρηση τους στη θεραπεια της ηπατιτιδας c
CY1111705T1 (el) Παραγωγα 2-αζα-δικυκλο[3.1.0]εξανιου ως ανταγωνιστες του υποδοχεα ορεξινης
CY1106801T1 (el) Νεες ετεροκυκλικες ενωσεις, η παρασκευη τους και η χρηση τους ως φαρμακα, ιδιαιτερα ως αντιβακτηριακα
CY1110956T1 (el) Παραγωγα πυριδο-πυραζινης χρησιμα ως ζιζανιοκτονες ενωσεις
CY1110419T1 (el) Τρικυκλικες ενωσεις με βαση το 1,6-διυδρο-1,3,5,6-tetpaaza-as-ινδακενιο και φαρμακευτικες συνθεσεις που τις περιεχουν ως αναστολεις της ενζυμικης ενεργοτητας της ικκ
CY1109677T1 (el) Παραγωγα κινολινης και χρηση αυτων ως μυκοβακτηριακων αναστολεων
CY1110962T1 (el) Τρικυκλικες ενωσεις και η χρηση τους ως διαμορφωτες του υποδοχεα γλυκοκορτικοειδων